Role of Slc5a5 in the diagnosis and treatment of drug-resistant cancer

• Project/Area Number: 24K10435
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Juntendo University
• Principal Investigator: ハイジッヒ ベアーテ 順天堂大学, 大学院医学研究科, 特任准教授 (30372931)
• Project Period (FY): 2024-04-01 – 2027-03-31
• Project Status: Granted (Fiscal Year 2024)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2026: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2025: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2024: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: Leukemia / drug resistance

Outline of Research at the Start

A fundamental problem in leukemia treatment is how to overcome drug resistance. Leukemic cells evade drug effects by enhancing multidrug resistance protein 1 (MDR1; ABCB1 gene). MDR1 pumps foreign substances, including chemotherapeutic drugs, out of cells. Defective apoptosis is another drug resistance mechanism.

AIM1: Evaluate SLC5A5 expression in human hematopoietic/stromal cells of myeloid leukemia patients and normal controls before and after ATRA/dexamethasone or myelosuppression

AIM2. Determine proliferation/apoptosis after myelosuppression with/ without I- and I2 addition